IFNG and melanoma: Treatment of mice with IFNγ-ADSCs or IFNγ/TRAIL-ADSCs demonstrated a statistically significant increase in the median survival of melanoma bearing mice, while most of the animals in other groups died by day 40 (Figure 7A).